Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Operating Expenses (2020 - 2025)

Ovid Therapeutics' Operating Expenses history spans 6 years, with the latest figure at $13.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 20.49% year-over-year to $13.0 million; the TTM value through Dec 2025 reached $49.7 million, down 20.43%, while the annual FY2025 figure was $49.7 million, 20.43% down from the prior year.
  • Operating Expenses reached $13.0 million in Q4 2025 per OVID's latest filing, up from $12.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $31.8 million in Q1 2021 to a low of $10.8 million in Q4 2024.
  • Average Operating Expenses over 5 years is $15.7 million, with a median of $13.8 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 56.82% in 2021, then tumbled 53.63% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $26.4 million in 2021, then crashed by 53.63% to $12.2 million in 2022, then skyrocketed by 50.01% to $18.3 million in 2023, then plummeted by 41.09% to $10.8 million in 2024, then increased by 20.49% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Operating Expenses are $13.0 million (Q4 2025), $12.7 million (Q3 2025), and $11.3 million (Q2 2025).